JUND

Across TCGA pan-cancer cohorts, JUND mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JUND data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher JUND mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated JUND expression acts as an unfavorable survival marker.

CCRCC, PDAC, and HNSC are the cancer types where JUND mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.238	0.915	.010	6	view →
PDAC	DFS	Median	II,III,IV	0.312	0.489	.033	5	view →
HNSC	OS	Tertile	All	0.567	0.763	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

JUND–CCRCC (DFS)

Open the CCRCC breakdown →